Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(antihemophilic factor recombinant Fc fusion protein)
77 results
  • Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim? [Review]
    Front Immunol 2019; 10:1196Schifferli A, Nimmerjahn F, Kühne T
  • Fc fusion proteins and Fc fusion peptides or peptibodies are chimeric molecules composed of an active pharmacological protein or peptide and the Fc fragment of an immunoglobulin. The primary aim of this drug construct is to prolong the half-life of the active component. This molecular architecture is seen in drugs, such as etanercept, romiplostim, and the recombinant factor VIII (efmoroctocog alf…
  • Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization. [Journal Article]
    Blood Adv 2018; 2(21):2904-2916Kis-Toth K, Rajani GM, … Loh C
  • The main complication of replacement therapy with factor in hemophilia A (HemA) is the formation of inhibitors (neutralizing anti-factor VIII [FVIII] antibodies) in ∼30% of severe HemA patients. Because these inhibitors render replacement FVIII treatment essentially ineffective, preventing or eliminating them is of top priority in disease management. The extended half-life recombinant FVIII Fc fu…
  • Prevention and Management of Bleeding Episodes in Children with Hemophilia. [Review]
    Paediatr Drugs 2018; 20(5):455-464Ljung RCR
  • Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administra…
  • Recombinant factor VIII: past, present and future of treatment of hemophilia A. [Review]
    Drugs Today (Barc) 2018; 54(4):269-281Raso S, Hermans C
  • The development of recombinant factor VIII (rFVIII) was initially driven by the necessity to treat hemophilia A (HA) patients with FVIII concentrates without the risk of transmitting infectious agents. Over the last three decades the safety of rFVIII has been further improved by completely removing animal or human proteins from the manufacturing process, so that patients would not be exposed to k…
New Search Next